EicOsis Launches EC5026 Phase 1b Trial

EicOsis Human Health, a pharmaceutical firm, has embarked on a Phase 1b clinical trial for EC5026, a groundbreaking soluble epoxide hydrolase inhibitor (sEHI) intended for pain management. The company, which focuses on developing non-narcotic oral analgesics, has initiated this trial to assess the safety of EC5026 through multiple ascending doses over a week-long period. The trial, which is double-blind and placebo-controlled, has yielded initial findings with no significant adverse effects observed.
EC5026, characterized by its potency and selectivity as an sEH inhibitor, is pivotal in managing the metabolism of signaling lipids and addressing inflammation and stress responses triggered by injury or illness. By inhibiting sEH, EC5026 helps to reduce pain by avoiding the breakdown of endogenous analgesic and anti-inflammatory lipids, offering a non-opioid alternative for treating moderate to severe pain conditions. Preclinical research has shown that EC5026 does not induce sedation, adverse behavioral impacts, or addiction tendencies.
The discovery of the enzyme inhibitor can be credited to Bruce Hammock, a distinguished professor at UC Davis and the founder of EicOsis, who also has a role at the UC Davis Comprehensive Cancer Center. Hammock's research has shed light on the regulatory role of degradation in controlling various biological processes, including inflammation and pain management.
Dr. William K Schmidt, the Vice President of Clinical Development at EicOsis, has voiced optimism regarding the Phase 1b trial, highlighting the drug's promising safety and tolerability profile. The company is also planning to conduct its first patient study in April 2024, focusing on individuals with spinal cord injuries who have not found relief with current non-opioid pain medications. EC5026 has received Fast Track designation from the FDA, reflecting the urgent need for safe and effective non-opioid pain treatments.
Cindy McReynolds, CEO of EicOsis, has emphasized the importance of the Phase 1b trial's initiation as a milestone for the company, showcasing the team's commitment to advancing treatments for serious diseases. The NIH has backed the clinical trial progression of EC5026 through various initiatives, including the Small Business Innovation Research program and the Helping to End Addiction Long-term Initiative.
EicOsis, a name derived from eicosanoids, which are key chemical mediators in the arachidonate cascade, is dedicated to providing safer and more effective pain management options. Irene Cortes-Puch, a clinical scientist at EicOsis, has expressed excitement about the trial's potential to contribute to the company's mission.
Chronic pain affects approximately 50 million Americans, imposing an annual economic burden of $560 billion when considering medical costs, lost productivity, and disability claims. Further details on the Phase 1b clinical study can be accessed through ClinicalTrials.gov under the identifier NCT06089837.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!